Search results for "cost"

showing 10 items of 5421 documents

Maristem stem cells of marine/aquatic invertebrates: from basic research to innovative applications

2018

The “stem cells” discipline represents one of the most dynamic areas in biomedicine. While adult marine/aquatic invertebrate stem cell (MISC) biology is of prime research and medical interest, studies on stem cells from organisms outside the classical vertebrate (e.g., human, mouse, and zebrafish) and invertebrate (e.g., Drosophila, Caenorhabditis) models have not been pursued vigorously. Marine/aquatic invertebrates constitute the largest biodiversity and the widest phylogenetic radiation on Earth, from morphologically simple organisms (e.g., sponges, cnidarians), to the more complex mollusks, crustaceans, echinoderms, and protochordates. These organisms contain a kaleidoscope of MISC-type…

0301 basic medicinemarine/aquatic invertebratesQH301 Biologymarine/aquatic invertebrateBioactive moleculesT-NDASGeography Planning and Developmentlcsh:TJ807-830BiodiversitySettore BIO/05 - ZoologiaStem cellsblue biotechnology0302 clinical medicineBioactive moleculeBasic researchaging ; bioactive molecules ; blue biotechnology ; cancer ; cell culture ; COST Action ; Europe ; marine/aquatic invertebrates ; regeneration ; stem cellsGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)lcsh:Environmental sciencesCancerlcsh:GE1-350quinonessea-urchin eggsStem cellGeographyPolicy and LawEcologylcsh:Environmental effects of industries and plantsManagementEuropeMarine/aquatic invertebrateStem cellCèl·lules mareEuropean communityMonitoringaging; bioactive molecules; blue biotechnology; cancer; cell culture; COST Action; Europe; marine/aquatic invertebrates; regeneration; stem cellslcsh:Renewable energy sourcesCOST ActionAging; Bioactive molecules; Blue biotechnology; Cancer; Cell culture; COST Action; Europe; Marine/aquatic invertebrates; Regeneration; Stem cells; Geography Planning and Development; Renewable Energy Sustainability and the Environment; Management Monitoring Policy and LawManagement Monitoring Policy and LawBiologyQH30103 medical and health sciencesSDG 3 - Good Health and Well-beingNear neighborunitsstem cellsbioactive moleculesevolutioncancerSDG 14 - Life Below WaterRenewable Energy14. Life underwaterSH Aquaculture. Fisheries. AnglingSHRegeneration (ecology)BiologyBiomedicineInvertebratePlanning and Developmentcell cultureScience & TechnologySustainability and the EnvironmentRenewable Energy Sustainability and the Environmentbusiness.industryMarine invertebratesagingInvertebrats marinsbioactive moleculecell_developmental_biology030104 developmental biologylcsh:TD194-19513. Climate actionregenerationproteinbusiness030217 neurology & neurosurgery
researchProduct

Les modifications de pratique clinique liées à l’arrivée du séquençage haut débit dans le diagnostic génétique des maladies du développement

2018

Abstract Introduction The arrival of high-throughput sequencing (HTS) has led to a sweeping change in the diagnosis of developmental abnormalities (DA) with or without intellectual deficiency (ID). With the prospect of deploying these new technologies, two questions have been raised: the representations of HTS among geneticists and the costs incurred due to these analyses. Methods Geneticists attending a clinical genetics seminar were invited to complete a questionnaire. The statistical analysis was essentially descriptive and an analysis of costs was undertaken. Results Of those responding to the questionnaire, 48% had already prescribed exome analysis and 25% had already had the occasion …

0301 basic medicinemedicine.medical_specialtyMedical practice3. Good health03 medical and health sciences030104 developmental biologyFamily medicinePediatrics Perinatology and Child HealthmedicineCost analysisMedical geneticsGenomic medicineStatistical analysisPsychologyExomeArchives de Pédiatrie
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Toward evidence-based severity assessment in rat models with repeated seizures: I. Electrical kindling

2018

Objective: Rodent epilepsy models can significantly contribute to our understanding of pathophysiological mechanisms and to validation of biomarker and target candidates. Evidence-based severity assessment is a presupposition for the ethical evaluation of animal experimentation allowances as well as for the development of efficacious refinement concepts. Methods: Aiming to improve our understanding of the impact of experimental procedures and repeated seizures, we have completed a comprehensive behavioral and biochemical analysis assessing various parameters that can inform about the influence of an electrical kindling paradigm on well-being in rats. Thereby, we have focused on the immediat…

0301 basic medicinemedicine.medical_specialtyNeurologyStreSeverity of Illness Index3RRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compoundEpilepsy0302 clinical medicineSeizuresCorticosteroneKindling NeurologicmedicineAnimalsInterpersonal RelationsAnimal testingBehaviorLaboratory animalEpilepsyKindlingbusiness.industryBehavioral patternmedicine.diseaseElectrodes ImplantedRatsDisease Models AnimalDistress030104 developmental biologyNeurologychemistryBiomarker (medicine)FemaleNeurology (clinical)CorticosteronebusinessNeuroscience030217 neurology & neurosurgeryEpilepsia
researchProduct

Fundamentals and implementation of Microbiological Diagnostic Stewardship Programs.

2021

Microbiological diagnostic stewardship programs promote coordinated measures aimed at optimizing the use of diagnostic techniques, thus favouring the adoption of adequate and cost-effective therapeutic, clinical and preventive decisions. The implementation of microbiological diagnostic stewardship relies upon the creation of multidisciplinary committees led by clinical microbiologists for the design of diagnostic algorithms, the adequacy of the laboratory computer system to monitor the relevance of the requested diagnostic tests, the implementation of a quality control system, the design and performance of studies of cost-effectiveness, the training of the petitioner and the technical and n…

0301 basic medicinemedicine.medical_specialtyNursing staffbusiness.industryCost effectivenessDiagnostic Tests RoutineCost-Benefit Analysis030106 microbiologyDiagnostic algorithmsCommunicable Diseases03 medical and health sciences0302 clinical medicineContinuous evaluationQuality control systemMultidisciplinary approachMedicineHumansMedical physics030212 general & internal medicineStewardshipbusinessRoutine careEnfermedades infecciosas y microbiologia clinica (English ed.)
researchProduct

Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia

2019

Background & Aims: Non-alcoholic fatty liver disease and alcohol-related liver disease pose an important challenge to current clinical healthcare pathways because of the large number of at-risk patients. Therefore, we aimed to explore the cost-effectiveness of transient elastography (TE) as a screening method to detect liver fibrosis in a primary care pathway. Methods: Cost-effectiveness analysis was performed using real-life individual patient data from 6 independent prospective cohorts (5 from Europe and 1 from Asia). A diagnostic algorithm with conditional inference trees was developed to explore the relationships between liver stiffness, socio-demographics, comorbidities, and hepati…

0301 basic medicinemedicine.medical_specialtyTransient elastographyPopulationLiver fibrosisDisease03 medical and health sciencesLiver disease0302 clinical medicineFibrosisInternal medicinemedicineeducationeducation.field_of_studyAlcohol-related liver diseaseHepatologybusiness.industryFatty liverCost-effectiveness analysismedicine.disease3. Good health030104 developmental biologyStratified screening030211 gastroenterology & hepatologyTransient elastographybusinessHepatic fibrosisNon-alcoholic fatty liver disease
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

European contribution to the study of ROS : A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

2017

WOS: 000410470000009

0301 basic medicinereactive oxygen species ; reactive nitrogen species ; redox signaling ; oxidative stress ; antioxidants ; redox therapeuticsRedox signalingInternational CooperationSMOOTH-MUSCLE-CELLS[SDV]Life Sciences [q-bio]Clinical BiochemistryISCHEMIA-REPERFUSION INJURYReviewddc:616.07Bioinformaticsmedicine.disease_causeBiochemistryAntioxidants0302 clinical medicineENDOPLASMIC-RETICULUM STRESSCost actionlcsh:QH301-705.5ComputingMilieux_MISCELLANEOUSmedia_commonlcsh:R5-920Redox therapeuticsReactive nitrogen species3. Good healthVariety (cybernetics)MANGANESE SUPEROXIDE-DISMUTASECHRONIC GRANULOMATOUS-DISEASERisk analysis (engineering)ddc:540lcsh:Medicine (General)Oxidation-ReductionSignal TransductionSocieties ScientificPULMONARY ARTERIAL-HYPERTENSIONMedicinaEstrès oxidatiuBiology03 medical and health sciencesAntioxidants ; Oxidative Stress ; Reactive Nitrogen Species ; Reactive Oxygen Species ; Redox Signaling ; Redox TherapeuticsJournal Articlemedicinemedia_common.cataloged_instanceAnimalsHumans[CHIM]Chemical SciencesEuropean UnionEuropean unionNITRIC-OXIDE SYNTHASETANDEM MASS-SPECTROMETRYMolecular BiologyMITOCHONDRIAL OXIDATIVE STRESSGROWTH-FACTOR-BETAOrganic ChemistryDisease progressionBiology and Life SciencesOxidation reductionManganese Superoxide Dismutase030104 developmental biologylcsh:Biology (General)Oxidative stressReactive oxygen species030217 neurology & neurosurgeryOxidative stressRedox biology
researchProduct

Le déploiement d'un pilotage stratégique des coûts dans les services informatiques de deux groupes internationaux : perspective instrumentale et anal…

2011

This article analyses the strategic cost management stream with an instrumental point of view and two case studies. We try to show in what extend the Activity-based Costing developments could be included in a strategic approach of the management accounting and to test if the ABC is a relevant tool to drive the strategy. The first part synthesizes the strategic cost management developments which try to improve the Activity-based Costing method. In the first part, we describe them using the Strategic Management Accounting stream, with a link with cost management and ABC. The second part exposes a taxonomy of the reasons why using the ABC method. In a third part, we confront our developments t…

05 social sciences050201 accountingStrategic cost managementPilotage stratégique des coûtsJEL : M - Business Administration and Business Economics • Marketing • Accounting • Personnel Economics/M.M4 - Accounting and Auditing/M.M4.M41 - AccountingActivity-based CostingDispositifs à base d'activitésJEL: M - Business Administration and Business Economics • Marketing • Accounting • Personnel Economics/M.M4 - Accounting and Auditing/M.M4.M41 - Accounting0502 economics and businessEtudes de casStrategic cost managementActivity-based CostingCase studiesPilotage stratégique des coûtsDispositifs à base d'activitésEtudes de cas[SHS.GESTION]Humanities and Social Sciences/Business administrationCase studies[ SHS.GESTION ] Humanities and Social Sciences/Business administration[SHS.GESTION] Humanities and Social Sciences/Business administration050203 business & management
researchProduct

Assessing the costs and cost-effectiveness of ICare internet-based interventions (protocol)

2019

Background: Mental health problems are common and place a burden on the individual as well as on societal resources. Despite the existence of evidence-based treatments, access to treatment is often prevented or delayed due to insufficient health care resources. Effective internet-based self-help interventions have the potential to reduce the risk for mental health problems, to successfully bridge waiting time for face-to-face treatment and to address inequities in access. However, little is known about the cost-effectiveness of such interventions. This paper describes the study protocol for the economic evaluation of the studies that form the ICare programme of internet-based interventions …

050103 clinical psychologyCost effectivenessService uselcsh:BF1-990Psychological interventionHealth InformaticsHealth informaticsArticleH03 medical and health sciences0302 clinical medicineSDG 17 - Partnerships for the GoalsHealth care/dk/atira/pure/core/keywords/600089002Psychology0501 psychology and cognitive sciences030212 general & internal medicineUnit costCost databaseCost-utilityActuarial sciencelcsh:T58.5-58.64business.industrylcsh:Information technology05 social sciences1. No poverty/dk/atira/pure/sustainabledevelopmentgoals/partnershipsInternet-based interventionsEconomic evaluation3. Good healthlcsh:PsychologyEconomic evaluationThe InternetCost-effectivenessMental healthbusiness
researchProduct